Evidence map›Paper›PMID 40820992›Full record

ArticleFrontiers in chemistry2025

Design and synthesis of 3,4-

Chunyu Gao, Hongbo Teng, Wenxin Zhang, Yaru Zhao, Chunguo Cui, Zerbo Patrice, Liyan Wang, Yan Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chunyu Gao *College of Chinese Medicinal Materials, Jilin Agricultural University, Changchun, Jilin, China.
Hongbo Teng *College of Chinese Medicinal Materials, Jilin Agricultural University, Changchun, Jilin, China.
Wenxin Zhang *College of Chinese Medicinal Materials, Jilin Agricultural University, Changchun, Jilin, China.
Yaru Zhao *College of Chinese Medicinal Materials, Jilin Agricultural University, Changchun, Jilin, China.
Chunguo Cui *Breast Surgery Department of Bethune Third Hospital, Jilin University, Changchun, Jilin, China.
Zerbo PatriceDépartement: Biochimie / Microbiologie UFR Sciences de la Vie et de la Terre, Ouagadougou, Burkina Faso.
Liyan WangCollege of Chinese Medicinal Materials, Jilin Agricultural University, Changchun, Jilin, China.
Yan ZhaoCollege of Chinese Medicinal Materials, Jilin Agricultural University, Changchun, Jilin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Due to the lack of effective treatment methods and targeted drugs, triple-negative breast cancer (TNBC) is not only difficult to treat clinically, but also has a poor prognosis for patients. This study aims to develop novel anti-TNBC drug candidates by designing 90 derivatives of 3,4- Methods: Firstly, 90 derivatives were synthesized and screened, and the compound I-27 showed excellent cytotoxicity (IC Results: In vitro tests showed that compound I.-27 could effectively inhibit the proliferation, migration and invasion of TNBC cells, and induce apoptosis. Transcriptomic analysis revealed that it has a dual mechanism of action. On the one hand, it inhibits tumor angiogenesis through the ID1/TSP-1 pathway. On the other hand, it promotes apoptosis through the PI3K/AKT/FoxO1 signaling pathway. In vivo tests, the compound significantly reduced tumor volume and inhibited lung metastasis through mouse models. It further confirmed that ID1 is a key target for anti-tumor. Conclusions: In this study, an anti-TNBC drug with multiple mechanisms was developed from the triterpenoids of 3,4-3,4-

Indexed as

angiogenesisapoptosisseco-lupane triterpene derivativestranscriptomicstriple-negative breast cancer

Identifiers

PMID40820992
PMCPMC12351286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.